10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 3 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
Liproxstatin-1 Liproxstatin-1 is a potent ferroptosis inhibitor with an IC50 of 22 nM.
In vitro
Liproxstatin-1 is able to inhibit ferroptosis in the low nanomolar range and inhibit the growth of Gpx4−/−cells with IC50 of 22 nM. Liproxstatin-1 (50 nM) completely prevents lipid peroxidation in Gpx4−/−cells. Liproxstatin-1 (200 nM) protects against FINs, such as BSO (10 µM), erastin (1 µM) and RSL3 (0.5 µM), in a dose dependent manner, whereas it fails to rescue cell death induced by staurosporine (0.2 µM) and H2O2 (200 µM).
In vivo
Liproxstatin-1 remarkably extends survival compared with the vehicle-treated group, delays ferroptosis in tubular cells, and mitigates tissue injury in ischaemia/reperfusion-induced liver injury.
Cell Data
cell lines：Dendritic cells (DCs) and CD4+ T cells
Concentrations：~200 nM
Incubation Time：~72 h
Powder Purity:≥97%
| ALogP | 2.598 |
|---|---|
| hba_count | 1 |
| HBD-Zahl | 3 |
| Rotationsfähige Bindung | 3 |
| Isomere SMILES | C1CNCCC12C(=NCC3=CC(=CC=C3)Cl)NC4=CC=CC=C4N2 |
|---|---|
| Molekulargewicht | 340.85 |
| Reaxy-Rn | 34084241 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=34084241&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| DMSO (mg/ml) Maximale Löslichkeit | 68 |
|---|---|
| DMSO (mM) Maximale Löslichkeit | 199.5012469 |
| Wasser (mg/ml) Maximale Löslichkeit | ＜1 |
| 1. Lei Shu, Peili Luo, Chuanyu Ren, Ziwei Lai, Xuejuan Zhang, Chuanbin Wu, Xin Pan, Zhengwei Huang. (2025) Inhalable Fibroin Hybrid Liposomes for the Targeted Treatment of Lung Adenocarcinoma via Autophagy-Enhanced Ferroptosis. ACS Nano, [PMID:40878028] [10.1021/acsnano.5c09493] |
| 2. Jing Lin, Xueli Yang, Cizhong Jiang, Xiaoguang Liu, Jiejun Shi. (2026) Enhancing cancer susceptibility to disulfidptosis by inducing cell cycle arrest and impairing DNA repair. Theranostics, 16 (2): (637). [PMID:41346703] [10.7150/thno.122956] |
| 3. Jiao Kong, Yujia Chen, Shuanghui Lu, Lvexiang Yuan, Tao He, Minlei Dong, Yingqiong Zhang, Xiaoyi Pan, Hui Zhou, Huidi Jiang. (2026) Pollen of Brassica campestris L. ameliorates hyperuricemic and obstructive nephropathy by targeting the β-catenin/TCF4-ferroptosis pathway. JOURNAL OF ETHNOPHARMACOLOGY, [PMID:41933742] [10.1016/j.jep.2026.121611] |
